

# Beslut vid Fru Berta Kamprads styrelsemöte 9 maj 2018

## **Bo Baldetorp, FBKS-2018-9**

*S-phase fraction as a measure of tumour cell proliferation in endometrioid endometrial cancer. Diagnostic, prognostic and predictive implications.*

Anslag beviljat: 2018-2019

## **Åke Borg, FBKS-2018-3**

*Breast cancer: molecular determinants of risk, prognosis and treatment – with focus on BRCAness tumors*

Anslag beviljat: 2018-2019

## **Crister Ceberg, FBKS-2018-25**

*Translational image-guided radiotherapy - dosimetry and radiobiological modelling*

Anslag beviljat: 2018

## **Sara Ek, FBKS-2018-7**

*Improved treatment selection through establishment of clinically actionable immune-related biomarker signatures for mantle cell lymphoma.*

Anslag beviljat: 2018-2019

## **Karin Fjordén FBKS-2018-12**

*Genomic Characterisation of Aggressive Lymphomas with Focus on Liquid Biopsies as a Potential Clinical Application*

Anslag beviljat: 2018-2019

## **Karin Jirström, FBKS-2018-15**

*Precision pathology and tumour monitoring in pancreatic and other periampullary cancers*

Anslag beviljat: 2018-2019

## **Siker Kimbung FBKS-2018-14**

*Towards individualization of chemotherapy treatment for preoperative and adjuvant therapy in breast cancer*

Anslag beviljat: 2018-2019

## **Anna Kwiecinska, FBKS-2018-23**

*Molecular characterisation of follicular lymphoma with respect to progression, transformation and prognostic markers.*

Anslag beviljat: 2018-2019

## **Anna-Maria Larsson, FBKS-2018-16**

*Translational studies of PODXL and EGFR-mediated signalling in gastrointestinal cancer*

Anslag beviljat: 2018-2019

**Selamawit Mekuria, FBKS-2018-5**

*HPV prevalence and genotypes in Ethiopia using vaginal self-test*

Anslag beviljat: 2018

**Emma Niméus, FBKS-2018-20**

*Proteogenomic signatures for improved prognosis in recurring breast cancer*

Anslag beviljat: 2018-2019

**Håkan Olsson, Lunds universitet, FBKS-2018-10**

*Genetic and environmental risk factors for common malignant tumours especially breast cancer, ovarian cancer and malignant melanoma.*

Anslag beviljat: 2018-2019

**Maria Planck, FBKS-2018-17**

*A translational approach to improved lung cancer therapy*

Anslag beviljat: 2018-2019

**Elisabeth Rasmusson, FBKS-2018-6**

*Evaluation of dose-response associations in internal and external radiotherapy of prostate cancer*

Anslag beviljat: 2019

**Carlos Rovira, FBKS-2018-1**

*New treatment for Her2 positive cancer*

Anslag beviljat: 2018-2019

**Lisa Rydén, FBKS-2018-18**

*Tamoxifen response in premenopausal breast cancer by molecular subtypes in a randomized trial with long-term follow-up*

Anslag beviljat: 2018-2019

**Johan Staaf, FBKS-2018-4**

*Genomiska markörer för DNA reparations skador i trippelnegativ bröstcancer - nya terapeutiska möjligheter*

Anslag beviljat: 2018-2019

**Johan Vallon-Christersson, FBKS-2018-11**

*Deriving prognostic and predictive biomarkers in breast cancer using refined proteome measurements*

Anslag beviljat: 2018-2019

**Ann Rosendahl och Marie Klintman, FBKS-2018-22**

*Translationellt forskningsprojekt. Lönekostnader 100 % prekliniker + 50 % kliniker*

Anslag beviljat: 2018-2019